In vitro leishmanicidal activity of N-dodecyl-1,2-ethanediamine

Biomedicine and Pharmacotherapy

Volumn 66, Issue 3, 2012, Pages 180-186

  Silva, Alexandre L Neves ^a   Adade, Camila M ^b   Shoyama, Fernanda M ^a   Neto, Cecílio Purcino S ^a   Padrón, Thaís S ^b   de Almeida, Mauro V ^c   Rezende, Carlos A de Magalhães ^c   Silva, Claudio V ^a   Souza, Maria A ^a  

^a FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

Author keywords

Diamine; Leishmania; Leishmanicidal activity

Indexed keywords

AMPHOTERICIN B; ANTILEISHMANIAL AGENT; N DODECYL 1,2 ETHANEDIAMINE; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL EXPERIMENT; ARTICLE; AUTOPHAGY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; LEISHMANIA; LEISHMANIA BRAZILIENSIS; LEISHMANIA CHAGASI; LEISHMANICIDAL ACTIVITY; MACROPHAGE; MAMMAL CELL; MOUSE; NONHUMAN; PERITONEAL EXUDATE CELL; PRIORITY JOURNAL; PROMASTIGOTE; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; ANTIPROTOZOAL AGENTS; CELL LINE, TUMOR; CELLS, CULTURED; DNA REPLICATION; ETHYLENEDIAMINES; HUMANS; LEISHMANIA; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; PARASITES;

EID: 84860233999     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2011.10.005     Document Type: Article

References (23)

1. Ready P.D. Leishmaniasis emergence in Europe. Euro Surveill 2010, 15:19505.
2. Gonzalez U., Pinart M., Reveiz L., Rengifo-Pardo M., Tweed J., Macaya A., et al. Designing and reporting clinical trials on treatments for cutaneous leishmaniasis. Clin Infect Dis 2010, 51:409-419.
3. Gontijo B., de Carvalho Mde L. American cutaneous leishmaniasis. Rev Soc Bras Med Trop 2003, 36:71-80.
4. Tempone A.G., Taniwaki N.N., Reimao J.Q. Antileishmanial activity and ultrastructural alterations of Leishmania (L.) chagasi treated with the calcium channel blocker nimodipine. Parasitol Res 2009, 105:499-505.
5. Santos D.O., Coutinho C.E., Madeira M.F., Bottino C.G., Vieira R.T., Nascimento S.B., et al. Leishmaniasis treatment--a challenge that remains: a review. Parasitol Res 2008, 103:1-10.
6. Croft S.L., Engel J. Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives. Trans R Soc Trop Med Hyg 2006, 100(Suppl. 1):S4-S8.
7. Chappuis F., Sundar S., Hailu A., Ghalib H., Rijal S., Peeling R.W., et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?. Nat Rev Microbiol 2007, 5:873-882.
8. Giordani R.B., Araujo D.P., Duarte M., Zuanazzi J.A., Tasca T., De Almeida M.V. Anti-protozoal activity of diamine derivatives. Biomed Pharmacother 2011, 65:60-62.
9. Delgado G., Sánchez Y., Plaza D., Mariño A., Granados D. Anexperimental approach to studying the effectiveness and safety of meglumine antimoniate formulations. Biomed Pharmacother. 2011, 10.1016/j.biopha.2010.12.016.
10. del Olmo E., Alves M., Lopez J.L., Inchaustti A., Yaluff G., Rojas de Arias A., et al. Leishmanicidal activity of some aliphatic diamines and amino-alcohols. Bioorg Med Chem Lett 2002, 12:659-662.
11. Junior C.O., Alves R.O., Rezende C.A., da Costa C.F., Silva H., Le Hyaric M., et al. Trypanocidal activity of lipophilic diamines and amino-alcohols. Biomed Pharmacother 2010, 64:624-646.
12. Tavares J., Ouaissi A., Lin P.K., Tomas A., Cordeiro-da-Silva A. Differential effects of polyamine derivative compounds against Leishmania infantum promastigotes and axenic amastigotes. Int J Parasitol 2005, 35:637-646.
13. Labadie G.R., Choi S.R., Avery M.A. Diamine derivatives with antiparasitic activities. Bioorg Med Chem Lett 2004, 14:615-619.
14. Biagini G.A., Richier E., Bray P.G., Calas M., Vial H., Ward S.A. Heme binding contributes to antimalarial activity of bis-quaternary ammoniums. Antimicrob Agents Chemother 2003, 47:2584-2589.
15. Calas M., Ancelin M.L., Cordina G., Portefaix P., Piquet G., Vidal-Sailhan V., et al. Antimalarial activity of compounds interfering with Plasmodium falciparum phospholipid metabolism: comparison between mono- and bisquaternary ammonium salts. J Med Chem 2000, 43:505-516.
16. Coimbra E.S., de Almeida M.V., Júnior C.O., Taveira A.F., da Costa C.F., de Almeida A.C., et al. Synthesis and antileishmanial activity of lipidic amino-alcohols. Chem Biol Drug Des 2010, 75:233-235.
17. Vannier-Santos M.A., Menezes D., Oliveira M.F., de Mello F.G. The putrescine analogue 1,4-diamino-2-butanone affects polyamine synthesis, transport, ultrastructure and intracellular survival in Leishmania amazonensis. Microbiology 2008, 154:3104-3111.
18. Herrmann H.O., Gercken G. Metabolism of 1-0-[1'-14C]octadecyl-sn-glycerol in Leishmania donovani promastigotes. Ether lipid synthesis and degradation of the ether bond. Mol Biochem Parasitol 1982, 5:65-76.
19. Basselin M., Robert-Gero M. Alterations in membrane fluidity, lipid metabolism, mitochondrial activity, and lipophosphoglycan expression in pentamidine-resistant Leishmania. Parasitol Res 1998, 84:78-83.
20. da Costa C.F., Coimbra E.S., Braga F.G., dos Reis R.C., da Silva A.D., de Almeida M.V. Preparation and antileishmanial activity of lipophilic N-alkyl diamines. Biomed Pharmacother 2009, 63:40-42.
21. Giordani R.B., De Almeida M.V., Fernandes E., França da Costa C., De Carli G.A., Tasca T., et al. Anti-Trichomonas vaginalis activity of synthetic lipophilic diamine and amino-alcohol derivatives. Biomed Pharmacother 2009, 63:613-617.
22. Docampo R., Moreno S.N. Acidocalcisomes. Cell Calcium 2011, 50:113-119.
23. Menna-Barreto R.F., Salomão K., Dantas A.P., Santa-Rita R.M., Soares M.J., Barbosa H.S., et al. Different cell death pathways induced by drugs in Trypanosoma cruzi: an ultrastructural study. Micron 2009, 40:157-168.